Your session is about to expire
← Back to Search
Cortisol Synthesis Inhibitor and Benzodiazepine Receptor Agonist
EMB-001 for Tobacco Use Disorder
Phase 1 & 2
Waitlist Available
Research Sponsored by Embera NeuroTherapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up weeks 9-12
Awards & highlights
No Placebo-Only Group
Summary
This trial tests EMB-001, a combination of two drugs that reduce stress and anxiety, to help adult smokers quit smoking over a few months.
Eligible Conditions
- Tobacco Use Disorder
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ weeks 9-12
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~weeks 9-12
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Smoking Abstinence
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: EMB-001 ActiveExperimental Treatment1 Intervention
720 mg metyrapone/24 mg oxazepam mg BID, for a total daily dose of 1440 mg metyrapone and 48 mg oxazepam
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
EMB-001
2016
Completed Phase 2
~100
Find a Location
Who is running the clinical trial?
Foundation for a Smoke-Free WorldOTHER
9 Previous Clinical Trials
1,062 Total Patients Enrolled
2 Trials studying Tobacco Use Disorder
75 Patients Enrolled for Tobacco Use Disorder
Embera NeuroTherapeutics, Inc.Lead Sponsor
6 Previous Clinical Trials
203 Total Patients Enrolled
2 Trials studying Tobacco Use Disorder
49 Patients Enrolled for Tobacco Use Disorder
Foundation for a Smoke Free World INCOTHER
14 Previous Clinical Trials
2,133 Total Patients Enrolled
2 Trials studying Tobacco Use Disorder
75 Patients Enrolled for Tobacco Use Disorder
Share this study with friends
Copy Link
Messenger